[144] QuantumScape Corp SEC Filing
QuantumScape Corp (QS) notice reports a proposed sale of 9,800 shares of common stock to be executed through Goldman Sachs & Co. LLC on 09/12/2025 on the NYSE. The shares were acquired on 08/15/2024 as restricted stock units received as compensation from the issuer. The filing lists an aggregate market value of 97,510 (consistent with the number shown) and reports total shares outstanding of 522,939,205. The filer states there were no securities sold in the past three months for the account and includes the standard representation that the selling person is not aware of undisclosed material adverse information.
- Disclosure compliance: The filer provides required Rule 144 details including broker, acquisition date, and sale date.
- Clear acquisition source: Shares were acquired as restricted stock units (compensation), explicitly stated in the filing.
- No prior sales: The filing reports "Nothing to Report" for securities sold in the past three months for this account.
- Insider sale scheduled: The notice documents a planned sale of 9,800 shares, which could be perceived negatively by some investors despite being small.
Insights
TL;DR: Routine insider sale of compensation shares; size appears immaterial relative to outstanding shares.
The filing documents a proposed sale of 9,800 common shares acquired as RSUs on 08/15/2024, to be sold via Goldman Sachs on 09/12/2025. Relative to the reported 522,939,205 shares outstanding, the transaction represents a de minimis fraction, indicating limited direct impact on supply or market liquidity. The filing fulfills Rule 144 disclosure requirements and confirms no other sales in the prior three months for this account. From a market-impact perspective this is a routine compliance filing rather than a material corporate development.
TL;DR: Compliance-focused disclosure showing RSU vesting and planned sale; no red flags in the notice.
The notice indicates the shares were granted as compensation and lists broker, share count, acquisition date, and planned sale date, meeting the Rule 144 disclosure elements. The signer affirms absence of undisclosed material adverse information and there are no reported sales in the prior three months. This documentation supports transparency around insider liquidity but, given the small lot size relative to total outstanding shares, it is unlikely to signal governance or control changes.